Read by QxMD icon Read

Mobility in end-stage prostate cancer

Chu-Biao Zhao, Ji-Ming Bao, Yong-Jie Lu, Tong Zhao, Xin-Hua Zhou, Da-Yong Zheng, Shan-Chao Zhao
Receptor for advanced glycation end products (RAGE), along with its ligand high mobility group box 1 (HMGB1), is believed to play an important role in prostate cancer. The aim of this retrospective study was to investigate the expression of RAGE and HMGB1 and their clinical impact on prostate cancer progression and prognosis. The expression of RAGE and HMGB1 was assessed by immunohistochemistry in cancer lesions from 85 confirmed prostate cancer cases. We determined the potential association between the expression level of these two proteins and the clinicopathological features and overall patient survival...
2014: American Journal of Cancer Research
Moammir H Aziz, Nancy E Dreckschmidt, Ajit K Verma
Prostate cancer (PCa) is the second leading cause of cancer-related deaths in men. Hormone-refractory invasive PCa is the end stage and accounts for the majority of PCa patient deaths. We present here that plumbagin (PL), a quinoid constituent isolated from the root of the medicinal plant Plumbago zeylanica L., may be a potential novel agent in the control of hormone-refractory PCa. Specific observations are the findings that PL inhibited PCa cell invasion and selectively induced apoptosis in PCa cells but not in immortalized nontumorigenic prostate epithelial RWPE-1 cells...
November 1, 2008: Cancer Research
J M Cózar Olmo, J Carballido Rodriguez, P Luque Galvez, A G Tabernero Gómez, A Barreiro Mouro, E Sánchez Sánchez, C González Enguita, J Alcover García, E Garcia-Galisteo, J M Abascal García, M Sanchez Chapado, F GómezVeiga, R J Minguez Martínez, A Rodriguez Antolin, R A Medina López, M Rico Morales, F J Regadera Sejas, S Búcar Terrades, D Jamardo Gonzalez, R Gálvez
OBJECTIVES: To assess the effectiveness and tolerability of zoledronic acid in prostate cancer patients with bone metastases at the hormone-sensitive (HS) and hormone-independent (HI) stages. MATERIALS AND METHODS: A nationwide, observational, prospective, open and multi-centre trial was devised, with a total of 218 male patients diagnosed with prostate cancer at the HS stage (36%) or HI stage (64%) who were administered zoledronic acid (4 mg/IV/month for 6 months) in addition to their specific oncological treatment...
May 2008: Actas Urologicas Españolas
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"